Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Total Liabilities (2020 - 2025)

Historic Total Liabilities for Mereo BioPharma (MREO) over the last 6 years, with Q3 2025 value amounting to $7.0 million.

  • Mereo BioPharma's Total Liabilities fell 5679.21% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year decrease of 5679.21%. This contributed to the annual value of $15.4 million for FY2024, which is 338.93% down from last year.
  • Per Mereo BioPharma's latest filing, its Total Liabilities stood at $7.0 million for Q3 2025, which was down 5679.21% from $8.5 million recorded in Q2 2025.
  • Mereo BioPharma's Total Liabilities' 5-year high stood at $89.8 million during Q2 2021, with a 5-year trough of $7.0 million in Q3 2025.
  • Moreover, its 5-year median value for Total Liabilities was $16.1 million (2023), whereas its average is $26.5 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first plummeted by 338.93% in 2024, then crashed by 5679.21% in 2025.
  • Mereo BioPharma's Total Liabilities (Quarter) stood at $51.8 million in 2021, then tumbled by 49.77% to $26.0 million in 2022, then tumbled by 38.63% to $16.0 million in 2023, then decreased by 3.39% to $15.4 million in 2024, then plummeted by 54.58% to $7.0 million in 2025.
  • Its Total Liabilities stands at $7.0 million for Q3 2025, versus $8.5 million for Q2 2025 and $8.2 million for Q1 2025.